![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 37, 26071-26078, September 10, 1999
§¶,
,
,
,
, and
§
From the Stress response elements, which mediate induction
of the mouse heme oxygenase-1 (HO-1) gene by several agents, resemble
the binding site for the activator protein-1 (Jun/Fos), Maf, and
Cap'n'Collar/basic leucine zipper (CNC-bZIP) families of proteins. In
L929 fibroblasts, significant activation of an HO-1 enhancer-reporter
fusion gene was observed only with the CNC-bZIP class of proteins with
Nrf2 exhibiting the highest level of
trans-activation, between 25- and 30-fold. To further
examine the role of this factor in HO-1 gene regulation, a
dominant-negative mutant, Nrf2M, was generated and conditionally
expressed in L929 cells. The mutant protein was detected in cytoplasmic
and nuclear fractions but did not affect cell growth. Under conditions
of Nrf2M overexpression, HO-1 mRNA accumulation in response
to heme, cadmium, zinc, arsenite, and
tert-butylhydroquinone was inhibited by 85-95%. In
contrast, overexpression of a dominant-negative mutant of c-Jun
decreased L929 cell growth but did not inhibit HO-1 gene activation.
Nrf2 does not homodimerize, but CNC-bZIP·small Maf protein
heterodimers and Nrf2·Jun protein complexes are proposed to
function as trans-activators. Co-expression of Jun proteins
or p18, however, had no significant affect or inhibited
Nrf2-mediated trans-activation. Taken together, these results implicate Nrf2 in the induction of the HO-1 gene but suggest that the Nrf2 partner in this function is a factor other than p18 or Jun proteins.
Heme oxygenase enzymes catalyze the first and rate-limiting step
in heme1 catabolism, the
oxidative cleavage of b-type heme to yield equimolar quantities of iron, carbon monoxide and biliverdin. Biliverdin is
subsequently converted to bilirubin by the action of biliverdin reductase. The expression of one isoform of heme oxygenase, HO-1, is
dramatically stimulated by a variety of agents including the substrate
heme, heavy metals, hyperthermia, UV irradiation, and inflammatory
cytokines. The realization that most, if not all, HO-1 inducers
stimulate production of reactive oxygen species or deplete glutathione
levels or both, and the fact that heme is a potent pro-oxidant whereas
bilirubin is an equipotent anti-oxidant, has led to the postulate that
HO-1 activity is a component of the cellular defense mechanism against
oxidant stress. This hypothesis has been experimentally verified by
numerous studies using both in vitro and in vivo
models of oxidant injury (reviewed in Ref. 1).
While the induction of HO-1 has been extensively documented and is
known to be regulated primarily at the level of gene transcription, the
molecular mechanism(s) underlying this response is poorly understood.
Our analyses of the mouse HO-1 gene have identified two 5' distal
enhancer regions at approximately The consensus StRE also resembles the optimal recognition sequences,
TGCTGAGTCAGCA (9) and (T/C)GCTGA(G/C)TCA(C/T) (10), of the v-Maf
oncoprotein and of NF-E2, respectively. The v-Maf oncoprotein, encoded
by the avian musculoaponeurotic fibrosarcoma virus AS42 (11), is the
founding member of the Maf family of sequence-specific DNA-binding
proteins, of which six cellular members have also been identified to
date. Maf factors, like Jun and Fos proteins, contain the basic leucine
zipper (bZIP) domain for DNA binding and dimerization. Three of the Maf
members, the small Maf proteins, lack apparent
trans-activation domains. NF-E2, an erythroid-specific
transcription factor that is required for The optimal recognition sequences for v-Maf and NF-E2, as noted above,
are extended AP-1 binding sites. The 3-base pair extension, (T/C)GC, is
critical for high affinity binding of these factors to their target
sequences. In a recent report (19), we demonstrated that mutation of
this 3-base extension in the context of the StRE, while leaving intact
the AP-1 heptad, abolished activation of a linked reporter gene in
response to heme and cadmium, suggesting that factors other than AP-1
proteins are responsible for this induction. In the present report, we
provide data that implicate Nrf2 in
inducer-dependent activation of the HO-1 gene.
Materials--
Restriction endonucleases and other DNA modifying
enzymes were purchased from either Life Technologies, Inc. or New
England Biolabs. Radiolabeled nucleotides were obtained from NEN Life Science Products. Heme (as hemin chloride) was purchased from Porphyrin
Products. Enzymes and reagents for chloramphenicol acetyltransferase and luciferase assays were purchased from Sigma. All other chemicals were reagent grade.
Plasmid Constructs--
Mammalian expression plasmids were
kindly provided by Drs. Stuart Orkin (p45, Nrf2, p18, and p18M),
Mark Kerppola (c-Maf), and Tom Curran (c-Fos). cDNA clones were
kindly provided by Dr. Minami Matsui (Fra-1 and Fra-2) or purchased
from American Type Culture Collection (ATCC) (c-Jun, JunB, and JunD)
and the appropriate cDNA fragments were cloned downstream of the
Rous sarcoma virus long terminal repeat in the mammalian expression
vector pRSV. Plasmids for tetracycline-dependent mammalian
gene expression (pUHD15.1 and pUHD10-3) were kindly provided by Dr.
Herman Bujard. The dominant-negative mutants of Nrf2 and c-Jun,
Nrf2M and c-JunM, were generated by polymerase chain reaction
amplification of the respective mouse cDNAs with oligonucleotide
pairs 5'-GCACGCGGCCGCCATGGGTGAATCCCAATG-3' and
5'-CCTCCGGATCCTAGTTTTTCTTTGTATCTG-3' and
5'-GCACGCGGCCGCCATGGTCTACGCCAACCT-3' and
5'-ACAGTGGATCCTCAAAACGTTTGCAACTGC-3', respectively. The amplification products were cloned downstream of the elongation factor-1 Cell Culture, Transfection, and Enzyme Assays--
Mouse
macrophage RAW 264.7 and fibroblast L929 cells were purchased from ATCC
and maintained in Dulbecco's modified Eagle's medium containing
0.45% glucose and 10% fetal bovine serum. The L929 subclone E8.T4
(20) was cultured in the same medium supplemented with 200 µg/ml
Geneticin (G418 sulfate) and 1 µg/ml tetracycline. Transient and
stable transfections were carried out by the calcium phosphate
precipitation technique as described previously (4). Briefly, for
transient assays, cells were seeded (~5 × 105/60-mm
plate) 16 h prior to transfection. Cells were exposed to the
DNA-CaPO4 precipitate for 6 h, shocked by a 1-min
treatment with 10% glycerol in phosphate-buffered saline, and cultured
for an additional 24 h in complete medium. Preparation of cell
extracts and measurement of CAT and luciferase activities were carried out as described previously (2). RNA Isolation and Analysis--
Total RNA was isolated by the
procedure of Sacchi and Chozymski (22), and Northern blot analysis was
carried out as described previously (23). For RNA dot blot analysis, 5 µg of total RNA was transferred to Zeta-Probe (Bio-Rad) nylon
membrane according to the manufacturer's instructions. Hybridization
and washing conditions for dot blots were identical to those for
Northern blots. Western Blot Analysis--
Confluent cells from one 60-mm plate
were harvested in cold phosphate-buffered saline and pelleted by
centrifugation at 8,000 rpm for 1 min at 4 °C. Cells were
resuspended in 100-200 µl of lysis buffer (50 mM Hepes
(pH 7.5), 1.5 mM NaCl, 1.5 mM
MgCl2, 1 mM EGTA, 10% glycerol, 1% Triton
X-100, 0.1 mM phenylmethylsulfonyl fluoride, and 1 µg/ml
antipain, chymostatin, leupeptin, and pepstatin A) and left on ice for
10 min. Cytoplasmic extracts were separated from the nuclei by
centrifugation. Nuclear and whole cell extracts were prepared by direct
lysis in 1× electrophoresis sample buffer (62.5 mM
Tris-HCl (pH 6.8), 2% SDS, 10% glycerol). Protein concentration was
determined using the Bio-Rad DC protein assay kit. Twenty microgram
samples were size-fractionated on a 15% SDS-polyacrylamide gel and
protein blot analysis was carried out using the ECL Western blotting
system (Amersham Pharmacia Biotech) according to the manufacturer's
recommendation. Antibodies to Nrf2 and c-Jun were obtained from
Santa Cruz Biotechnology and used at dilutions recommended by the manufacturer.
trans-Activation of the SX2 Enhancer by CNC-bZIP
Proteins--
Members of the AP-1 (2, 4, 5), CNC-bZIP (see below), and
Maf (see below)2 families of
proteins bind to one or more of the StREs in the HO-1 gene enhancers.
The role, if any, of these sequence-specific DNA-binding proteins in
HO-1 gene transcriptional regulation was examined by transient
trans-activation assays. L929 cells were co-transfected with
expression plasmids encoding individual factors and an
SX2-dependent CAT reporter gene construct. The effect of the factors on SX2 transcription activity was assessed by measurement of CAT activity in cell extracts. Of the AP-1 family members tested, only the combination of c-Jun and c-Fos increased SX2 activity (~1.5-fold) (Fig. 1). Individual
members decreased enhancer activity to varying degrees (20-60% of
basal level). c-Maf did not alter SX2 activity, whereas small Maf/p18
inhibited SX2-dependent transcription by approximately
90%. Only members of the CNC-bZIP family of proteins exhibited
significant trans-activation ( Development of a Dominant-negative Mutant of Nrf2--
To
further characterize the role of Nrf2 in HO-1 gene regulation,
we devised a methodology to inhibit Nrf2 function. Nrf2, like Jun proteins, contains an N-terminal transcription activation domain and C-terminal dimerization and DNA-binding domains (17). Deletion of the transcription activation domain of c-Jun results in a
protein that functions as a dominant-negative mutant by virtue of
homodimerization with c-Jun and heterodimerization with c-Jun partners.
While Nrf2 does not homodimerize (Refs. 17, 27, and 28; see
below), we reasoned that a similar mutant of Nrf2 could inhibit
Nrf2 function by sequestering Nrf2 dimerization partner(s) and competing for Nrf2 recognition sequences. We,
therefore, generated a mutant of Nrf2, Nrf2M, lacking the
activation domain by deleting amino acid residues 1-392 (numbering as
in Ref. 29). The effect of Nrf2M on Nrf2 function was
assessed in transient trans-activation assays. As shown in
Fig. 2, overexpression of Nrf2M
completely blocked Nrf2-mediated trans-activation of
the SX2 enhancer in both L929 and E8.T4 cells. In the latter cells, CAT
activity was reduced below basal values.
Characterization of L929 Cells Expressing the Nrf2
Dominant-negative Mutant--
To examine the effect of the Nrf2
dominant-negative mutant on HO-1 gene induction, we generated L929
clones stably expressing Nrf2M. Because of the possibility that
inhibition of the Nrf2 transcription factor would affect cell
proliferation or viability, Nrf2M was expressed in a regulated
manner. DNA encoding Nrf2M was cloned downstream of
tet operator (tetO) sequences in plasmid pUHDBG
(20). The resultant clone, pUHDBG/Nrf2M was stably transfected into E8.T4 cells, a subclone of L929 cells that expresses the tetracycline (Tc)-regulated trans-activator (30), a chimeric transcription factor that regulates gene expression via tetO
sequences and whose activity is inhibited in the presence of Tc. Six
individual transfectants (N1-N6) were isolated and examined for
Tc-regulated gene expression by RNA dot blot analysis using a rabbit
Overexpression of Nrf2M Attenuates HO-1 Gene
Induction--
To determine if Nrf2M overexpression and, by
inference, inhibition of Nrf2 function, affects HO-1 gene
regulation, N2 cells were grown in the absence or presence of 1 µg/ml
Tc and treated with various HO-1 inducers, including heme, cadmium,
zinc, arsenite, and tert-butylhydroquinone (TBHQ). HO-1 gene
induction was assessed by measuring HO-1 mRNA levels in Northern
and dot blot analyses (Figs. 4 and
5). In the presence of Tc
(i.e. undetectable expression of Nrf2M), these agents
increased the steady-state amount of HO-1 mRNA by 15-90-fold above
basal levels. The magnitude of inductions is similar to that observed
in the parental E8.T4 and wild-type L929 cells (data not shown).
Overexpression of Nrf2M ( A Dominant-negative Mutant of c-Jun Does Not Inhibit HO-1 Gene
Activation--
For comparative purposes we also generated a
dominant-negative mutant of c-Jun, c-JunM, lacking the N-terminal
activation domain (residues 1-148), which is similar to one previously
described (31). As expected of a dominant-negative protein, c-JunM
inhibited c-Jun-mediated trans-activation of a reporter gene
(Fig. 6A). Initial attempts to
develop an E8.T4 cell line conditionally expressing c-JunM were
unsuccessful, so we subsequently transfected L929 cells with a plasmid
permitting constitutive expression of the mutant protein. Of 12 G418-resistant colonies selected, 9 clones survived during subsequent
culturing, two of which, cJM-9 and cJM-11, expressed the mutant protein
at high levels (Fig. 6B). Compared with cells transfected
with the empty vector ("Neo" cells), cJM-9 and cJM-11 cells
exhibited reduced rates of proliferation, particularly at lower levels
of serum (Fig. 6C). The decrease in cell growth correlated
with a 30-50% reduction in nuclear AP-1 DNA binding activity, as
judged by electrophoretic mobility shift assays (data not shown). In
contrast to Nrf2M, expression of c-JunM did not inhibit HO-1
mRNA induction by any of the agents tested (Fig. 6D).
Indeed, c-JM-9 and c-JM-11 cells exhibited a bias toward increased
levels of HO-1 mRNA accumulation. An opposite tendency was observed
with respect to c-Jun mRNA levels under basal conditions and in
response to the agents tested (Fig. 6D).
Nrf2 Heterodimerizes with Small Maf/p18 but the
Nrf2·p18 Heterodimer Functions as a Transcription
Repressor--
Based on the sequence of its leucine zipper domain,
Nrf2 is not expected to form homodimers (17) and does not bind
to the NF-E2 class of recognition sequences (27, 28). Heterodimers of
Nrf2 and small Maf proteins (27, 28) and Nrf2·Jun
complexes (32), however, can bind DNA and are reported to function as transcription activators. Similarly, using in vitro
synthesized proteins in electrophoretic mobility shift assay reactions,
the Nrf2·p18 heterodimer exhibited avid binding to the HO-1
StRE, but no such binding was observed with Nrf2 and c-Jun
co-translation products or any of the individual proteins (data not
shown). The lack of DNA binding by Nrf2 and c-Jun co-translation
products is consistent with a previous report demonstrating that an
uncharacterized cytosolic factor is required for Nrf2·c-Jun
complex formation and/or DNA binding activity (32).
To determine if the trans-activation of the SX2 enhancer by
Nrf2 (see Fig. 1) is due to Nrf2·p18 heterodimers, we
examined the effect of p18 on the Nrf2-independent and
Nrf2-dependent expression of pSX2 Induction of the mouse HO-1 gene by several diverse agents is
mediated by multiple StREs located within two distal 5' enhancer regions. The consensus sequence for the StRE resembles the binding site
for AP-1, Maf, and CNC-bZIP families of transcription factors, which
bind to DNA as obligate dimers. Because of intrafamily homodimerization and heterodimerization and even interfamily heterodimerization (9, 10,
13, 33-35), the number of dimeric species that can potentially bind to
the StREs is quite large (at least 20 such species can be formed within
and between Jun and Fos families alone), and identification of the
dimeric species that regulate HO-1 gene expression is not a trivial
matter, especially considering the possibility of inducer-specific
utilization of distinct dimeric factors. The present study represents
an initial attempt to identify, or at least narrow the list of, dimeric
species that mediate HO-1 gene induction.
Given that the AP-1 transcription factor system is a primary regulator
(along with NF- First, in transient trans-activation experiments, Jun and
Fos proteins generally do not affect or inhibit, whereas CNC-bZIP proteins potently stimulate, the transcription activity of the SX2
enhancer in L929 cells. This pattern is also observed in other cells
including Hepa (mouse hepatoma) and RAW 264.7 and MCF-7 (human breast
cancer epithelial) cells (data not shown), attesting to the generality
of this phenomenon. The trans-activation profile of SX2 is
strikingly similar to that of the antioxidant response element (ARE) of
the human NAD(P)H:quinone oxidoreductase (hNQO1) gene (36).
The NQO1 ARE contains a core sequence, TGCTGAGTCA, that
conforms perfectly to the consensus StRE and NF-E2 binding site and,
like the StRE, binds to both AP-1 and CNC-bZIP factors, but only the
latter stimulate transcription activity (36). As observed with SX2, Jun
and Fos family members either had no effect or inhibited
ARE-dependent reporter gene expression and Nrf2 was a more potent trans-activator than Nrf1. AREs, in response
to electrophiles and antioxidants, regulate the coordinate induction of
several genes encoding phase II enzymes - proteins which function in
xenobiotic detoxification and as such provide protection against electrophile and oxidative toxicity. Interestingly, many of the monofunctional phase II enzyme inducers also activate the HO-1 gene by
an StRE-dependent mechanism (37). Furthermore, the
hNQO1 ARE (38, 39) and the HO-1 StRE (2, 5, 37) mediate induction of the hNQO1 and HO-1 genes, respectively, in
response to 12-O-tetradecanoylphorbol 13-acetate, hydrogen
peroxide, and TBHQ. Given the similarities outlined above, it is not
unreasonable to speculate that activation of the NQO1 and
HO-1 genes, at least by common inducers, is mediated by the same
transcription factor(s). In this regard it is noteworthy that
stimulation of NQO1 gene expression by the phase II enzyme
inducer butylated hydroxyanisole is impaired in
nrf2 null mice (40). Additional indirect evidence of
a role for Nrf2 in HO-1 gene regulation is provided by the recent identification of Keap1, a protein that represses Nrf2 activity by cytoplasmic retention of the transcription factor (41).
Interestingly, electrophilic agents antagonize Keap1 repression, permitting nuclear translocation of Nrf2 and subsequent
activation of ARE-dependent genes.
Transient trans-activation experiments, as carried out in
this study, do not directly address the mechanism of
inducer-dependent HO-1 gene activation. More direct
evidence for a role of Nrf2 in this process is provided by the
observed inhibition of HO-1 gene induction by a dominant-negative
mutant of Nrf2. Interestingly, overexpression of Nrf2M
inhibits HO-1 mRNA accumulation in response to multiple agents,
implying a commonality in the induction mechanism. The simplest
explanation for this observation is that a single, Nrf2-containing dimeric factor is responsible for induction by all agents tested. Or, if distinct dimeric species are utilized in an
inducer-specific manner, then Nrf2 is a common subunit of such
factors. An alternative explanation for the inhibition of HO-1 gene
induction by all agents tested is that Nrf2M, after dimerization
with cellular factors such as the small Maf proteins, binds to the
StREs with such avidity as to interfere with the binding of the actual
positive activators. By extension, it is formally possibly that
Nrf2 does not in fact mediate induction by any of the agents
examined. While such a possibility cannot be ruled out, the potent
trans-activation of SX2 by Nrf2 (and the lack of such
activation by AP-1 members) strongly suggests that Nrf2 is a
positive regulator of HO-1 gene induction.
Unlike Nrf2M, expression of c-JunM does not inhibit activation
of the HO-1 gene and in fact appears to slightly enhance such induction. This latter tendency and the generally negative effect of
AP-1 factors on SX2 trans-activation are more consistent
with an inhibitory or neutral role of AP-1 proteins in HO-1 gene
regulation, at least in response to the agents used in this study. In
contrast to the results presented here, Elbirt et al. (8)
have recently reported that ectopic expression of a c-Jun
dominant-negative mutant abrogates arsenite-mediated induction of a
chicken HO-1 promoter-luciferase fusion gene in chicken embryo hepatoma
cells. One explanation for this discrepancy is that a truncated chicken HO-1 promoter fragment, lacking all of the potential
arsenite-responsive elements and one which is minimally responsive to
arsenite, was used in the latter study. An alternative explanation for
the lack of an effect of c-JunM, that stable overexpression of the
dominant-negative mutant provides a less complete inhibition of AP-1
activity than transient overexpression (as in Ref. 8), is unlikely
because: 1) stable expression of Nrf2M does not at all alter the
level of nuclear AP-1 binding activity (data not shown) but still
inhibits HO-1 mRNA accumulation and 2) transient transfection of an
expression plasmid encoding Nrf2M, but not c-JunM, inhibits
induction of an SX2/luciferase fusion gene by cadmium in MCF-7
cells.3
An important, but currently unresolved, issue is the identification of
the Nrf2 dimerization partner(s) that mediates induction of the
HO-1 gene. Nrf2 and other CNC-bZIP proteins prominently dimerize
with small Maf proteins, and these heterodimers are proposed to
positively regulate transcription via NF-E2 binding sites (27, 28, 42).
In general, co-transfection of small Maf expression plasmids enhances
the transcription of an NF-E2 site-dependent reporter gene
only slightly (20-50%) above that seen after transfection of the
CNC-bZIP encoding plasmid alone, and this enhancement may occur only
within a narrow range of CNC-bZIP/small Maf protein ratios (28). We,
however, find no evidence for p18-mediated stimulation of
Nrf2-dependent SX2 activity at any Nrf2 to
p18 ratio tested. Our results are similar to those of Johnson et
al. (43), who, based on the observed interference of Nrf1-mediated trans-activation by MafG, concluded that Nrf1·MafG
heterodimers function as negative regulators of the NF-E2 site. The
conclusion that Nrf2·p18 heterodimer does not mediate
inducer-dependent activation of the HO-1 gene is further
supported by the observation that this dimeric species binds to the TRE
of the collagenase gene (data not shown), a sequence element that is
not responsive to heme or cadmium (19).
Other potential Nrf2 partners include members of the Jun family
of proteins that interact with Nrf1 and Nrf2 to form complexes that are proposed to activate ARE-dependent gene expression
(32). For example, co-expression of c-Jun enhances Nrf2-mediated
trans-activation of the NQO1 ARE between 4- and
5-fold in human hepatoma cells. Like the small Maf proteins, Jun
proteins stimulate Nrf1- or Nrf2-mediated trans-activation only within a specific range of
CNC-bZIP/Jun protein ratio. Again Nrf2-mediated
trans-activation of SX2 is not stimulated by any of the Jun
proteins at any ratio tested, arguing against the role of
Nrf2·Jun complexes as mediators of the HO-1 gene induction.
This conclusion is also supported by the ineffectiveness of c-JunM in
inhibiting HO-1 gene activation.
In summary, Nrf2, a CNC-bZIP factor is a potent positive
regulator of the mouse HO-1 gene and mediates
inducer-dependent gene activation. Nrf2 functions as
an obligate heterodimer, but the partner(s) necessary for HO-1 gene
regulation is not known. This protein, however, is not p18 or a member
of the known Jun family of proteins. Studies to identify the
Nrf2 partner are currently in progress.
We thank Margret Overstreet for assistance in
preparation of the manuscript.
*
This work was supported by United States Public Health
Service Grants DK-43135 and HL60234.The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Dept. of Molecular
Genetics, Alton Ochsner Medical Foundation, 1516 Jefferson Hwy., New
Orleans, LA 70121. Tel.: 504-842-3314; Fax: 504-842-3381; E-mail:
jalam@ochsner.org.
2
J. Alam and D. Stewart, unpublished observations.
3
J. Alam, C. Dunne, D. Stewart, C. Touchard, S. Otterbein, and A. M. K. Choi, manuscript in preparation.
The abbreviations used are:
heme, ferriprotoporphyrin IX;
HO-1, heme oxygenase-1;
AP-1, activator
protein-1;
Nrf, NF-E2 related factor;
NF-E2, nuclear factor-erythroid
2;
CNC-bZIP, Cap'n'Collar/basic leucine zipper;
CAT, chloramphenicol
acetyltransferase;
StRE, stress response element;
ARE, anti-oxidant
response element;
Tc, tetracycline;
TBHQ, tert-butylhydroquinone.
Department of Molecular Genetics,
Section of Pulmonary and
Critical Care Medicine, Yale University School of Medicine,
New Haven, Connecticut 06250
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
4 and
10 kilobase pairs, termed
SX2 and AB1, respectively, that mediate transcriptional activation of
linked reporter genes in response to multiple agents including heme,
heavy metals, 12-O-tetradecanoylphorbol 13-acetate, arsenite, hydrogen peroxide, and lipopolysaccharide (2-6). Each enhancer region contains multiple copies of a cis-acting
element, termed the stress response element (StRE) (1) that are
essential for inducer-dependent gene activation. The
consensus StRE, (T/C)GCTGAGTCA, resembles the consensus binding site,
TGA(C/G)TCA, for the AP-1 class of transcription factors, comprised of
homo- and heterodimers of the Jun and Fos families of proteins, and we
initially proposed that such factors were responsible for HO-1 gene
activation (2, 4). This prediction was based on, among other reasons,
the observations that AP-1 proteins bound to individual StREs, that the
DNA binding of c-Jun·c-Fos heterodimer is subjected to redox regulation, and that expression and activities of some members of the
Jun and Fos family of protein are stimulated by many of the same agents
that induce HO-1 expression. A role for AP-1 proteins in HO-1 gene
regulation is further supported by recent studies demonstrating that
pharmacological inhibition of AP-1 activity attenuates
interleukin-1
- or tumor necrosis factor-
-mediated induction of
HO-1 mRNA levels in human endothelial cells (7) and ectopic
expression of a dominant-negative mutant of c-Jun inhibits
arsenite-mediated activation of the chicken HO-1 promoter in hepatoma
cells (8).
-globin synthesis in mouse
erythroleukemia cells (12), is a heterodimer of an erythroid-specific
45-kDa subunit (p45) and an ubiquitous polypeptide (p18), later
identified as the small Maf protein, MafK (10, 13, 14). p45, like AP-1
and Maf proteins, is a bZIP-type factor but also contains an upstream
Cap'n'Collar (CNC) domain homologous to a region within the fruit fly
homeotic selector protein encoded by the cap'n'collar gene
(15). Other CNC-bZIP polypeptides homologous to p45 have been
identified, including Nrf1 (16), Nrf2 (17), and Nrf3 (18),
which, unlike p45, are more widely expressed. Maf polypeptides resemble
Jun proteins in that they can homodimerize, whereas the CNC-bZIP
proteins, like Fos family members, can only form obligatory
heterodimers, most prominently with the small Maf factors.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
promoter (in plasmid pEF) or the tetracycline operator (in plasmid pUHDBG (20),
a variant of pUHD10-3). Plasmid pCMV
-gal was kindly provided by Dr.
Ping Wei. Plasmids pT109luc (21) and pRSVluc encode the firefly
luciferase gene under the control of the thymidine kinase promoter and
the Rous sarcoma virus long terminal repeat, respectively. Plasmid
pSX2
44luc was generated by replacing the chloramphenicol acetyltransferase (CAT) reporter gene in pSX2
44cat (4) with the
luciferase gene.
-Galactosidase activity was measured using the Galacto-Light (Tropix, Inc.) Chemiluminescent assay
kit according to the manufacturer's protocol. To generate stable
transfectants, E8.T4 or L929 cells were plated (1 × 106/10-cm plate) and transfected as described above with 13 µg of pUHDBG/Nrf2M plus 2 µg of pCEP4 (Invitrogen Corp.) or
with 15 µg of pEF/c-JunM, respectively. E8.T4 and L929 transfectants
were selected over a 3-week period in the presence of hygromycin (400 µg/ml) or G418 (800 µg/ml), respectively. Individual clones were isolated by limited dilution.
-32P-Radiolabeled hybridization probes
were generated by random priming of the rat HO-1 (24), mouse c-Jun,
chicken
-actin (25), or mouse Nrf2 cDNA fragments or
mouse MT-1 (26) or rabbit
-globin (20) genomic fragments.
Hybridization signals were quantified using a Storm PhosphorImager
(Molecular Dynamics). After signal quantization, the membranes were
stripped and re-hybridized to the
-actin probe. Relative mRNA
levels (see Figs. 5 and 6) were calculated after correcting for RNA
loading by normalizing the primary hybridization signal with the
-actin signal.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
5-fold) with Nrf2
increasing SX2 activity between 25- and 30-fold.

View larger version (17K):
[in a new window]
Fig. 1.
trans-Activation of the SX2
enhancer in L929 cells. Cells were transfected with a DNA mixture
consisting of 4 µg of pSX2
44cat, 4 µg of an empty expression
vector (
) or the indicated transcription factor expression plasmid,
and 2 µg of pT109luc. Aliquots representing 4% and 2% of the cell
extracts were used for CAT and luciferase assays, respectively.
Background CAT activity (from mock-transfected cells) was subtracted
from each experimental measurement, and the resulting value was
corrected for variation in transfection efficiency by normalization
with background-subtracted luciferase activity in the same cell
extract. Normalized activity for pSX2
44cat in the absence of
exogenous transcription factor was arbitrarily assigned a value of 1. Each data bar represents the average ± S.D.
from three to five independent experiments.

View larger version (13K):
[in a new window]
Fig. 2.
Inhibition of Nrf2-mediated
trans-activation by Nrf2M. L929 and E8.T4
cells were transfected with the indicated amount (in µg) of plasmid
mixtures. Normalized CAT activity was calculated as described in the
legend to Fig. 1. Each data bar represents the
average ± S.D. from three independent experiments.
-globin probe. (
-Globin sequences, present in pUHDBG, are fused
downstream of the Nrf2M translation termination site and provide
stability to the chimeric transcript.) All six clones exhibited
Tc-dependent regulation of the Nrf2M/
-globin
chimera (Fig. 3A). Northern
blot analysis of total RNA from N2 cells using an Nrf2 probe
identified an Nrf2M transcript of the predicted size
(approximately 750 bases) and the endogenous Nrf2 mRNA of
2.4 kilobases (Fig. 3B). The level of Nrf2M mRNA
was regulated by doxycycline, a tetracycline analogue, in a
dose-dependent manner over a range of approximately
100-fold. The Nrf2M protein was detected in both cytoplasmic and
nuclear fractions and migrated at a size corresponding to 27 kDa
(predicted size of 22.5 kDa) (Fig. 3C). The predicted size
of the native Nrf2 protein is 72 kDa, but the protein may
migrate anomalously above 90 kDa on an SDS-polyacrylamide gel (17).
Multiple, faint bands were observed in this region after longer
exposure of the Western blots (data not shown). The rates of growth of
N2 and N5 cells were not significantly different in the absence
(Nrf2M overexpression) or presence of 1 µg/ml Tc in the
culture media (Fig. 3D) and were similar to that of the
parental E8.T4 cells (data not shown).

View larger version (38K):
[in a new window]
Fig. 3.
A, screening of pUHDBG/Nrf2M
transfectants. Total RNA was isolated from individual clones (N1-N6)
cultured in the absence or presence of 1 µg/ml Tc. RNA dot blot
analysis was carried out as described in "Experimental Procedures"
using the probe for
-globin. The filter was autoradiographed for
8 h. B and C, tetracycline-regulated
expression of Nrf2M mRNA (B) and protein
(C). N2 cells were cultured for 72 h in the absence or
presence of the indicated concentration of doxycycline, a tetracycline
analogue. Northern blot analysis (B) was carried out using a
hybridization probe for Nrf2. Migration of the 18 and 28 S
ribosomal RNAs is indicated. The filter was autoradiographed for
16 h. Western blot analysis (C) was carried out as
described in "Experimental Procedures," and the filter was exposed
to film for 2 min. The size (kDa) and migration of the molecular size
standards are indicated. D, expression of Nrf2M does
not affect the rate of cell proliferation. 1 × 105
cells were seeded (t = 0) in duplicate 60-mm plates and
cultured in complete media in the absence or presence of 1 µg/ml Tc.
Cells were recovered by trypsinization at the indicated times, and
viable cells were quantified by the trypan blue exclusion method. Each
data bar represents the average ± S.D. from three
independent experiments.
Tc) inhibited HO-1 mRNA
accumulation by all inducers tested by 85-90%. The basal level of
HO-1 mRNA was not altered. Some of the HO-1 inducers, metals in
particular, activate the c-jun and metallothionein genes. These inductions, however, were not affected by Nrf2M,
indicating differences in gene activation mechanisms. Similar results
were observed with N5 cells (data not shown).

View larger version (50K):
[in a new window]
Fig. 4.
Expression of Nrf2M inhibits induction
of the HO-1 gene by multiple agents. E8.T4/Nrf2M (clone N2)
cells were plated (2 × 106/100 mm plate) and cultured
in the absence (
) or presence (+) of 1 µg/ml Tc for 48 h.
Cells were treated with vehicle, heme (10 µM),
CdCl2 (10 µM), ZnSO4 (100 µM), sodium arsenite (100 µM) or TBHQ (50 µM) for 3 h in serum-free medium in the absence or
presence of 1 µg/ml Tc. Total RNA was isolated, and 10-µg aliquots
were electrophoresed and transferred to nylon membrane. The filter was
hybridized to a rat HO-1 cDNA probe and autoradiographed for
18 h.

View larger version (21K):
[in a new window]
Fig. 5.
Nrf2M expression does not inhibit
induction of the c-jun and metallothionein genes.
Cells were treated as described in the legend to Fig. 4. RNA dot blot
analysis and quantization were carried out on triplicate filters using
probes for heme oxygenase-1, c-Jun, and metallothionein mRNAs, as
described in "Experimental Procedures." RNA levels in
vehicle-treated cells (Con) in the presence of tetracycline
were arbitrarily assigned values of 1. The data bars represent the average of two independent
experiments.

View larger version (29K):
[in a new window]
Fig. 6.
A, inhibition of c-Jun-mediated
trans-activation by c-JunM. RAW 264.7 cells were transfected
with the indicated amount (in µg) of plasmid mixtures. -Fold
trans-activation was calculated in a manner analogous to
that described in the legend to Fig. 1. Each data bar represents the average ± S.D. from three
independent experiments. B, identification of L929 stable
transfectants expressing c-JunM. Total cellular extracts were prepared
from clones transfected with the empty expression plasmid
(N) or with pEF/c-JunM (clone no. indicated). Western blot
analysis was carried out as described under "Experimental
Procedures," and the filter was exposed to film for 5 min. The size
(kDa) and migration of the molecular mass standards are indicated. The
bands between 40 and 46 kDa presumably represent endogenous Jun
proteins. C, expression of c-JunM decreases the rate of cell
proliferation. Control (Neo) or c-JunM-expressing cells were
cultured in 10% or 2% fetal bovine serum, and cell growth was
quantified as described in the legend to Fig. 3. D,
expression of c-JunM does not inhibit induction of the HO-1
gene. Cell treatment and RNA dot blot analysis were carried out as
described in the legends to Figs. 4 and 5. The probe fragment used to
detect endogenous c-Jun mRNA was derived from the 5' end of the
c-Jun cDNA and does not hybridize to c-JunM transcripts. The
data bars represent the average of two
independent experiments.
44luc in
transient transfection assays. In the absence of exogenous Nrf2
(Fig. 7A,
Nrf2), p18 decreased luciferase activity (by 90%)
in a dose-dependent manner. Although complexes of p18 with
other cellular factors cannot be ruled out, this down-regulation is
likely an effect of the p18·p18 homodimer as a mutant of p18, p18M,
which does not homodimerize (12), did not affect pSX2
44luc expression. Exogenous p18 also potently inhibited Nrf2
trans-activation of SX2 at all ratios of Nrf2 and p18
tested (Fig. 7A, +Nrf2). Co-expression of
p18M also inhibited Nrf2-mediated trans-activation but to a lesser extent (75% maximum inhibition versus
90% inhibition for p18) suggesting that, although it cannot
homodimerize, p18M does heterodimerize with Nrf2, albeit less
efficiently than p18. Co-expression of Jun-B and Jun-D also decreased
Nrf2-mediated trans-activation, but to a lesser
extent than that observed with p18 (Fig. 7B,
+Nrf2). Co-expression of c-Jun slightly enhanced (~20%) Nrf2-mediated trans-activation, but this
effect was not statistically significant.

View larger version (20K):
[in a new window]
Fig. 7.
p18 and Jun proteins do not enhance
Nrf2-mediated trans-activation of SX2.
L929 cells were transfected with DNA mixtures containing 4 µg of
pSX2
44 luc, 4 µg of pEF (
Nrf2), or 4 µg of
pEFNrf2 (+Nrf2), 1 µg of pCMV
-gal, and
the indicated amount of plasmid encoding p18 or p18M (A) or
Jun proteins (B). For each transfection, the total amount of
DNA was adjusted to 14 µg (A) or 17 µg (B)
with the appropriate empty expression vector. Aliquots of extracts
containing equivalent amounts of
-galactosidase activity
(approximately 4% of total protein) were used for luciferase
measurement. Normalized luciferase activity in the absence of exogenous
transcription factor was arbitrarily assigned a value of 1 (B). Each data point represents the
average ± S.D. from three to five independent experiments.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
B proteins) of the cellular response to alterations
in redox states, we initially reasoned that one or more members from
this family mediated HO-1 gene activation in response to oxidative
stress. Results presented herein, however, suggest that the CNC-bZIP
transcription factors play a more prominent role than AP-1 factors in
HO-1 gene induction. This conclusion is based on two principal
observations as discussed below.
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Choi, A. M. K.,
and Alam, J.
(1996)
Am. J. Respir. Cell. Mol. Biol.
15,
9-19[Abstract]
2.
Alam, J.,
and Den, Z.
(1992)
J. Biol. Chem.
267,
21894-21900 3.
Alam, J.,
Cai, J.,
and Smith, A.
(1994)
J. Biol. Chem.
269,
1001-1009 4.
Alam, J.
(1994)
J. Biol. Chem.
269,
25049-25056 5.
Alam, J.,
Camhi, S.,
and Choi, A. M. K.
(1995)
J. Biol. Chem.
270,
11977-11984 6.
Camhi, S.,
Alam, J.,
Otterbein, L.,
Sylvester, S. L.,
and Choi, A. M. K.
(1995)
Am. J. Respir. Cell. Mol. Biol.
13,
387-398[Abstract]
7.
Terry, C. M,
Clikeman, J. A.,
Hoidal, J. R.,
and Callahan, K. S.
(1998)
Am. J. Physiol.
274,
H883-H891
8.
Elbirt, K. K.,
Whitmarsh, A. J.,
Davis, R. J,
and Bonkovsky, H. L.
(1998)
J. Biol. Chem.
273,
8922-8931 9.
Kataoka, K.,
Noda, M.,
and Nishizawa, M.
(1994)
Mol. Cell. Biol.
14,
700-712 10.
Andrews, N. C.,
Erdjument-Bromage, H.,
Davidson, M. B.,
Tempst, P.,
and Orkin, S. H.
(1993)
Nature
362,
722-728[CrossRef][Medline]
[Order article via Infotrieve]
11.
Nishizawa, M.,
Kataoka, K.,
Goto, N.,
Fujiwara, K. T.,
and Kawai, S.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
7711-7715 12.
Kotkow, K. J.,
and Orkin, S. H.
(1995)
Mol. Cell. Biol.
15,
4640-4647[Abstract]
13.
Andrews, N. C.,
Kotkow, K. J.,
Ney, P. A.,
Erdjument-Bromage, H.,
Tempst, P.,
and Orkin, S. H.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11488-11492 14.
Igarashi, K.,
Itoh, K.,
Motohashi, H.,
Hayashi, N.,
Matuzaki, Y.,
Nakauchi, H.,
Nishizawa, M.,
and Yamamoto, M.
(1995)
J. Biol. Chem.
270,
7615-7624 15.
Mohler, J.,
Vani, K.,
Leung, S.,
and Epstein, A.
(1991)
Mech. Dev.
34,
3-10[CrossRef][Medline]
[Order article via Infotrieve]
16.
Chan, J. Y.,
Han, H.-L.,
and Kan, Y. W.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
11371-11375 17.
Moi, P.,
Chan, K.,
Asunis, I.,
Cao, A.,
and Kan, Y. W.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
9926-9930 18.
Kobayashi, A.,
Ito, E.,
Toki, T.,
Kogame, K.,
Takahashi, S.,
Igarashi, K.,
Hayashi, N.,
and Yamamoto, M.
(1999)
J. Biol. Chem.
274,
6443-6452 19.
Inamdar, N. M.,
Ahn, Y. I.,
and Alam, J.
(1996)
Biochem. Biophys. Res. Commun.
221,
570-576[CrossRef][Medline]
[Order article via Infotrieve]
20.
Wei, P.,
Ahn, Y. I.,
Housley, P. R.,
Alam, J.,
and Vedeckis, W. V.
(1998)
J. Steroid Biochem. Mol. Biol.
64,
1-12[CrossRef][Medline]
[Order article via Infotrieve]
21.
Nordeen, S. K.
(1988)
BioTechniques
6,
454-457[Medline]
[Order article via Infotrieve]
22.
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
23.
Alam, J.,
Shibahara, S.,
and Smith, A.
(1989)
J. Biol. Chem.
264,
6371-6375 24.
Shibahara, S.,
Muller, R.,
Taguchi, H.,
and Yoshida, T.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
7865-7869 25.
Cleveland, D. W.,
Lapota, M. A.,
Macdonald, R. J.,
Cowan, N. J.,
Rutter, W. J.,
and Kirschner, M. W.
(1980)
Cell
20,
95-105[CrossRef][Medline]
[Order article via Infotrieve]
26.
Alam, J.,
and Smith, A.
(1992)
J. Biol. Chem.
267,
16379-16384 27.
Itoh, K.,
Igarashi, K.,
Hayashi, N.,
Nishizawa, M.,
and Yamamoto, M.
(1995)
Mol. Cell. Biol.
15,
4184-4193[Abstract]
28.
Marini, M. G.,
Chan, K.,
Casula, L.,
Kan, Y. W.,
Cao, A.,
and Moi, P.
(1997)
J. Biol. Chem.
272,
16490-16497 29.
Chui, D. H. K.,
Tang, W.,
and Orkin, S. H.
(1995)
Biochem. Biophys. Res. Commun.
209,
40-46[CrossRef][Medline]
[Order article via Infotrieve]
30.
Gossen, M.,
and Bujard, H.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5547-5551 31.
Brown, P. H.,
Chen, T. K.,
and Birrer, M. J.
(1994)
Oncogene
9,
791-799[Medline]
[Order article via Infotrieve]
32.
Venugopal, R.,
and Jaiswal, A. K.
(1998)
Oncogene
17,
3145-3156[CrossRef][Medline]
[Order article via Infotrieve]
33.
Kerppola, T. K.,
and Curran, T.
(1994)
Oncogene
9,
675-684[Medline]
[Order article via Infotrieve]
34.
Kataoka, K.,
Fujiwara, K. T.,
Noda, M.,
and Nishizawa, M.
(1994)
Mol. Cell. Biol.
14,
7581-7591 35.
Kataoka, K.,
Igarashi, K.,
Itoh, K.,
Fujiwara, K. T.,
Noda, M.,
Yamamoto, M.,
and Nishizawa, M.
(1995)
Mol. Cell. Biol.
15,
2180-2190[Abstract]
36.
Venugopal, R.,
and Jaiswal, A. K.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14960-14965 37.
Prestera, T.,
Talalay, P.,
Alam, J.,
Ahn, Y. I.,
Lee, P. J.,
and Choi, A. M. K.
(1995)
Mol. Med.
1,
827-837[Medline]
[Order article via Infotrieve]
38.
Li, Y.,
and Jaiswal, A. K.
(1992)
J. Biol. Chem.
267,
15097-15104 39.
Li, Y.,
and Jaiswal, A. K.
(1994)
Eur. J. Biochem.
226,
31-39[Medline]
[Order article via Infotrieve]
40.
Itoh, K.,
Chiba, T.,
Takahashi, S.,
Ishii, T.,
Igarashi, K.,
Katoh, Y.,
Oyake, T.,
Hayashi, N.,
Satoh, K.,
Hatayama, I.,
Yamamoto, M.,
and Nabeshima, Y.
(1997)
Biochem. Biophys. Res. Commun.
236,
313-322[CrossRef][Medline]
[Order article via Infotrieve]
41.
Itoh, K.,
Wakabayashi, N.,
Katoh, Y.,
Ishii, T.,
Igarashi, K.,
Engel, J. D.,
and Yamamoto, M.
(1998)
Genes Dev.
13,
67-86
42.
Igarashi, K.,
Kataoka, K.,
Itoh, K.,
Hayashi, N.,
Nishizawa, M.,
and Yamamoto, M.
(1994)
Nature
367,
568-572[CrossRef][Medline]
[Order article via Infotrieve]
43.
Johnsen, O.,
Murphy, P.,
Prydz, H.,
and Kolsto, A.-B.
(1998)
Nucleic Acids Res.
26,
512-520
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
This article has been cited by other articles:
![]() |
D. C. Hassane, M. L. Guzman, C. Corbett, X. Li, R. Abboud, F. Young, J. L. Liesveld, M. Carroll, and C. T. Jordan Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data Blood, June 15, 2008; 111(12): 5654 - 5662. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mito, R. Ozono, T. Oshima, Y. Yano, Y. Watari, Y. Yamamoto, A. Brydun, K. Igarashi, and M. Yoshizumi Myocardial Protection Against Pressure Overload in Mice Lacking Bach1, a Transcriptional Repressor of Heme Oxygenase-1 Hypertension, June 1, 2008; 51(6): 1570 - 1577. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Brown, K. R. Sekhar, G. Rachakonda, S. Sasi, and M. L. Freeman Activating Transcription Factor 3 Is a Novel Repressor of the Nuclear Factor Erythroid-Derived 2 Related Factor 2 (Nrf2) Regulated Stress Pathway Cancer Res., January 15, 2008; 68(2): 364 - 368. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Seldon, G. Silva, N. Pejanovic, R. Larsen, I. P. Gregoire, J. Filipe, J. Anrather, and M. P. Soares Heme Oxygenase-1 Inhibits the Expression of Adhesion Molecules Associated with Endothelial Cell Activation via Inhibition of NF-{kappa}B RelA Phosphorylation at Serine 276 J. Immunol., December 1, 2007; 179(11): 7840 - 7851. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Sun, S. Zhang, J. Y. Chan, and D. D. Zhang Keap1 Controls Postinduction Repression of the Nrf2-Mediated Antioxidant Response by Escorting Nuclear Export of Nrf2 Mol. Cell. Biol., September 15, 2007; 27(18): 6334 - 6349. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Lin, S. Weis, G. Yang, Y.-H. Weng, R. Helston, K. Rish, A. Smith, J. Bordner, T. Polte, F. Gaunitz, et al. Heme Oxygenase-1 Protein Localizes to the Nucleus and Activates Transcription Factors Important in Oxidative Stress J. Biol. Chem., July 13, 2007; 282(28): 20621 - 20633. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. S. Cornblatt, L. Ye, A. T. Dinkova-Kostova, M. Erb, J. W. Fahey, N. K. Singh, M.-S. A. Chen, T. Stierer, E. Garrett-Mayer, P. Argani, et al. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast Carcinogenesis, July 1, 2007; 28(7): 1485 - 1490. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Marzec, J. D. Christie, S. P. Reddy, A. E. Jedlicka, H. Vuong, P. N. Lanken, R. Aplenc, T. Yamamoto, M. Yamamoto, H.-Y. Cho, et al. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury FASEB J, July 1, 2007; 21(9): 2237 - 2246. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Aleksunes and J. E. Manautou Emerging Role of Nrf2 in Protecting Against Hepatic and Gastrointestinal Disease Toxicol Pathol, June 1, 2007; 35(4): 459 - 473. [Abstract] [Full Text] [PDF] |
||||